

ESMO Preceptorship on Colorectal Cancer

PROGRAMME

**ESMO
PRECEPTORSHIP**

**VALENCIA SPAIN
9-10 MAY 2025**

CO-CHAIRS

Andrés Cervantes, Spain

Erika Martinelli, Italy

esmo.org

ESMO PRECEPTORSHIP PROGRAMME COLORECTAL CANCER

Multidisciplinary management, standards of care
and future perspectives

Valencia, Spain
9-10 May 2025

CO-CHAIRS

Andrés Cervantes, Spain
Erika Martinelli, Italy

SPEAKERS

Dimitri Dorcaratto, Spain
Michel Ducreux, France
Elena Élez, Spain
Claire Gallois, France
Carolina Martínez Ciarpaglini, Spain
Dominik Modest, Germany

LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology, histo- and moleculopathological prognostic factors
- To learn about sequencing of treatments, adverse events and special situations

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This educational programme has been supported by



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 9 May 2025

09:00-09:15 15'	Welcome and introduction	Andrés Cervantes, ES Erika Martinelli, IT
09:15-10:50 95'	SESSION 1 Localised colon cancer – Part 1	Chair: Andrés Cervantes, ES
30'	Quality and rules of a good pathology report: Histo- and moleculopathological biomarkers	Carolina Martínez Ciarpaglini, ES
30'	Adjuvant treatment for colon cancer stage II and III as standard of care	Michel Ducreux, FR
20'	Neoadjuvant chemotherapy for localised colon cancer as a potential option	Claire Gallois, FR
15'	Q&A	All
10:50-11:20	Coffee break	
11:20-12:30 70'	SESSION 2 Localised colon cancer – Part 2	Chair: Erika Martinelli, IT
30'	Neoadjuvant immunotherapy for localised colorectal cancer: Facts and future perspective	Claire Gallois, FR
10'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
12:30-13:30	Lunch	
13:30-14:50 80'	SESSION 3 Current first-line treatment for metastatic colorectal cancer	Chair: Andrés Cervantes, ES
40'	Recommendations according to ESMO guidelines: First-line strategy and specific subtypes	Erika Martinelli, IT
30'	Oligometastatic colorectal cancer: What to know about it and how to treat it	Dominik Modest, DE
10'	Q&A	All
14:50-15:20	Coffee break	
15:20-17:20 120'	SESSION 4 Metastatic colorectal cancer: Special clinical situations	Chair: Andrés Cervantes, ES
30'	How to integrate surgery in the treatment of patients with liver-only metastatic disease	Dimitri Dorcaratto, ES
45'	Presentation of three challenging clinical cases by the expert and faculty discussion	Dominik Modest, DE
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
20:30	Dinner	

Saturday, 10 May 2025

09:00-09:40 40'	SESSION 5 Localised rectal cancer	Chair: Erika Martinelli, IT
30'	Standard of care of localised rectal cancer	Andrés Cervantes, ES
10'	Q&A	All
09:40-11:55 105'	SESSION 6 Metastatic colorectal cancer: Maintenance and further lines	Chair: Andrés Cervantes, ES
20'	What to do after first-line failure?	Elena Élez, ES
20'	Treating patients with chemorefractory disease: Challenges and opportunities	Dominik Modest, DE
30'	Management of treatment-related side effects: <ul style="list-style-type: none"> - GI-toxicity - Neuropathy - Skin toxicity - Hypertension - Hand-foot syndrome 	Michel Ducreux, FR
10:50-11:20	Coffee break	
20'	How to deal with patients with BRAF mutant, G12C mutant and HER2 amplified advanced colorectal cancer after first failure	Erika Martinelli, IT
15'	Q&A	All
11:55-12:25 30'	SESSION 7 Metastatic colorectal cancer: Case discussion	Chair: Andrés Cervantes, ES
30'	Participants clinical case discussion (3x10')	Faculty
12:25-12:35 10'	Conclusion and farewell	Andrés Cervantes, ES Erika Martinelli, IT
12:35-13:35	Lunch	

Note: Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion